Fake, Poor-Quality Drugs Boosting Malaria Drug Resistance In Southeast Asia, U.S. Experts Say

“Fake or poor quality malaria drugs are boosting resistance in parts of southeast Asia, a problem that is likely to worsen unless tighter regulations are adopted, U.S. experts said Monday” at a hearing of the House Foreign Affairs Subcommittee on Africa, Global Health, and Human Rights, Agence France-Presse reports. “‘Drug resistance to the most effective drug available, artemisinin-based combination therapy, is developing and has been recognized in southeast Asia,'” Regina Rabinovich, director of infectious diseases at the Bill & Melinda Gates Foundation, said, according to the news service.

“‘Resistance is being noticed on the Thai, Cambodian, Burmese borders and resistance is likely to increase,'” Roger Bate of the American Enterprise Institute said, AFP notes. “In addition to tougher regulations, researchers need to focus on developing new drugs against malaria, and consider making sure they cannot be sold or distributed as mono-therapies, the panelists urged,” according to the news service (Sheridan, 12/5).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

The Henry J. Kaiser Family Foundation Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KaiserFamilyFoundation | twitter.com/kff

Filling the need for trusted information on national health issues, the Kaiser Family Foundation is a nonprofit organization based in San Francisco, California.